MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/600/0.01/21.03.25 | Real-time Bid/Ask 17:10:11 04/07/2024 BST | ||
| 0.147 EUR / 0.165 EUR | +6.85% |
|
| Current month | -8.18% | ||
| 1 month | -12.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 04/07/24 | 0.147 | +0.68% |
| 03/07/24 | 0.146 | -8.18% |
| 02/07/24 | 0.159 | +1.92% |
| 01/07/24 | 0.156 | -1.89% |
| 28/06/24 | 0.159 | -3.64% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 04:38 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG103D |
| ISIN | DE000MG103D5 |
| Date issued | 28/03/2024 |
| Strike | 600 $ |
| Maturity | 21/03/2025 (260 Days) |
| Parity | 100 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.213 € |
|---|---|
| Lowest since issue | 0.086 € |
| Spread | 0.018 € |
| Spread % | 10.91% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
